Trexquant Investment LP purchased a new position in shares of NeoGenomics (NASDAQ:NEO) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 44,301 shares of the medical research company’s stock, valued at approximately $361,000. Trexquant Investment LP owned approximately 0.05% of NeoGenomics at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NEO. Teacher Retirement System of Texas bought a new position in NeoGenomics in the 4th quarter valued at approximately $182,000. Howland Capital Management LLC lifted its stake in NeoGenomics by 67.6% in the 4th quarter. Howland Capital Management LLC now owns 21,782 shares of the medical research company’s stock valued at $193,000 after purchasing an additional 8,782 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in NeoGenomics in the 4th quarter valued at approximately $235,000. Aperio Group LLC bought a new position in NeoGenomics in the 4th quarter valued at approximately $243,000. Finally, FDx Advisors Inc. lifted its stake in NeoGenomics by 19.9% in the 1st quarter. FDx Advisors Inc. now owns 30,644 shares of the medical research company’s stock valued at $250,000 after purchasing an additional 5,091 shares during the last quarter. Institutional investors and hedge funds own 83.66% of the company’s stock.

NeoGenomics opened at $11.46 on Wednesday, Marketbeat Ratings reports. The company has a quick ratio of 1.85, a current ratio of 2.03 and a debt-to-equity ratio of 0.53. NeoGenomics has a 52-week low of $7.08 and a 52-week high of $11.63. The firm has a market cap of $914.20 million, a PE ratio of 191.00, a price-to-earnings-growth ratio of 5.97 and a beta of 0.41.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, May 1st. The medical research company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. NeoGenomics had a positive return on equity of 3.19% and a negative net margin of 0.86%. The business had revenue of $63.40 million for the quarter, compared to analyst estimates of $62.31 million. During the same quarter last year, the company earned $0.03 EPS. The business’s quarterly revenue was up 10.5% on a year-over-year basis. research analysts predict that NeoGenomics will post 0.1 EPS for the current year.

In other news, VP Jennifer Balliet sold 13,000 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $11.24, for a total transaction of $146,120.00. Following the sale, the vice president now owns 13,000 shares of the company’s stock, valued at approximately $146,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Steven A. Ross sold 81,999 shares of the firm’s stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $10.78, for a total value of $883,949.22. Following the sale, the insider now directly owns 4,500 shares in the company, valued at approximately $48,510. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by company insiders.

NEO has been the subject of several research reports. Royal Bank of Canada increased their price objective on shares of NeoGenomics from $23.00 to $24.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, February 23rd. First Analysis downgraded shares of NeoGenomics from an “overweight” rating to an “equal weight” rating and set a $11.00 price objective for the company. in a research note on Wednesday, May 2nd. Scotiabank increased their price objective on shares of NeoGenomics from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. Finally, BidaskClub raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $16.50.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.